R&D Centre
State-of-the-art R&D
set-up
Fully equipped Quality Control and Quality Assurance Laboratory
Pilot plant
cGMP facilities
Manufacturing facility
State-of-the-art manufacturing facility on the outskirts of Mumbai
Designed to comply with WHO, MHRA, USFDA, TGA, EU-GMP
DC Granules: up to 500 MT per annum
Finished Tablets: up to 500 million tablets per annum
Experienced team of personnel
Green Technology
Our proprietary direct-compression process is built on green technology eliminating solvents and reducing environmental impact without compromising quality.
Solvent-Free (OVI-Free)
clean, one-step manufacturing
Patient-Safe Formulations minimal excipient profile
.png)
Higher Waste-Management Standards
sustainable processing
.png)
Full EHS Compliance environment, health & safety
.png)
Tablet Manufacturing Capabilities
.png)
Advanced formulation
capabilities built
to meet global needs
.png)
Controlled dosing
.png)
IR, SR/XR, and ER
release profiles
.png)
Customised development with full
documentation support
.png)
Bilayer tablet technology
.png)
End-to-end support through
CDMO partnership
Therapeutic Categories
.png)
Diabetes
.png)
Pain Management
.png)
Cardiovascular
.png)
Central Nervous System
(CNS)
.png)
Antibiotic Therapies
.png)
Gastrointestinal
Compliances & Accreditations
EU-GMP and PIC/s audits are expected in the coming year.
With our R&D setup aimed primarily at DC Granules, YSK plans to develop and commercialize several other such APIs in its product portfolio.
YSK Laboratories' R&D division also plans to target companies’ desired products in which they face technical difficulties during the formulation steps and attempt to resolve them using in-house developed technologies.